MTIM
FULC icon

Marathon Trading Investment Management’s Fulcrum Therapeutics FULC Stock Holding History

Marathon Trading Investment Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,800
Closed -$67K – 295
2024
Q2 		$67K Sell
10,800
-34,200
-76% -$259K 0.01% 235
2024
Q1 		$425K Buy
+45,000
New +$402K 0.03% 187

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marathon Trading Investment Management's FULC Position: Q3 2024 in Review

Marathon Trading Investment Management sold out of Fulcrum Therapeutics (FULC) in Q3 2024, closing a stake of 10,800 shares — an estimated $67K sold.

Marathon Trading Investment Management first reported a position in FULC in Q1 2024 and held it in 2 quarters. The position peaked at $425K in Q1 2024. 130 funds tracked by Wall St. Rank hold FULC as of Q3 2024.

  • Marathon Trading Investment Management reported no remaining Fulcrum Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Marathon Trading Investment Management sold 10,800 Fulcrum Therapeutics shares in Q3 2024, an estimated $67K.
  • Marathon Trading Investment Management first reported a position in Fulcrum Therapeutics in Q1 2024 and held it in 2 quarters.
  • Marathon Trading Investment Management's Fulcrum Therapeutics position peaked at $425K in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2024.

Based on Marathon Trading Investment Management's 13F filing for Q3 2024, filed 7 Nov 2024.